title: Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with central nervous system involvement.
authors: a Department of Haematology , Peter MacCallum Cancer Centre , Melbourne , Victoria , Australia.
authors: Kah-Lok
authors: KL
authors: Chan
authors: a Department of Haematology , Peter MacCallum Cancer Centre , Melbourne , Victoria , Australia.
authors: Carrie
authors: C
authors: van der Weyden
authors: b Department of Anatomical Pathology , Peter MacCallum Cancer Centre , Melbourne , Victoria , Australia.
authors: Christine
authors: C
authors: Khoo
authors: b Department of Anatomical Pathology , Peter MacCallum Cancer Centre , Melbourne , Victoria , Australia.
authors: Stephen
authors: S
authors: Lade
authors: a Department of Haematology , Peter MacCallum Cancer Centre , Melbourne , Victoria , Australia.
authors: Piers
authors: P
authors: Blombery
authors: a Department of Haematology , Peter MacCallum Cancer Centre , Melbourne , Victoria , Australia.|c The Sir Peter MacCallum Department of Oncology , The University of Melbourne, Melbourne , Melbourne , Victoria , Australia.
authors: David
authors: D
authors: Westerman
authors: a Department of Haematology , Peter MacCallum Cancer Centre , Melbourne , Victoria , Australia.
authors: Amit
authors: A
authors: Khot
authors: d Celgene Corporation , Summit , NJ , USA.
authors: Brian
authors: B
authors: Melo
authors: c The Sir Peter MacCallum Department of Oncology , The University of Melbourne, Melbourne , Melbourne , Victoria , Australia.|e Peter MacCallum Cancer Centre, Cancer Therapeutics Program , Melbourne , Victoria , Australia.
authors: Ricky W
authors: RW
authors: Johnstone
authors: a Department of Haematology , Peter MacCallum Cancer Centre , Melbourne , Victoria , Australia.|c The Sir Peter MacCallum Department of Oncology , The University of Melbourne, Melbourne , Melbourne , Victoria , Australia.
authors: H Miles
authors: HM
authors: Prince
authors: a Department of Haematology , Peter MacCallum Cancer Centre , Melbourne , Victoria , Australia.
authors: Michael
authors: M
authors: Dickinson
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016543:Central Nervous System Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary*; D003520:Cyclophosphamide / Q000627:therapeutic use; D047630:Depsipeptides / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016130:Immunophenotyping; D016411:Lymphoma, T-Cell, Peripheral / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D012074:Remission Induction; D019233:Retreatment; D000069283:Rituximab; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D000903:Antibiotics, Antineoplastic; D058846:Antibodies, Monoclonal, Murine-Derived; D047630:Depsipeptides; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; C087123:romidepsin; D011241:Prednisone